科学家测试人体试验中细胞纤维化的可吸入基因疗法,目的是改善肺功能。 Scientists test inhalable gene therapy for cystic fibrosis in human trials, aiming to improve lung function.

伦敦帝国学院的研究人员正在对人体进行可吸入基因疗法的试验,这种疗法可以改善患有细胞纤维化的人的肺功能,而不论其具体基因突变情况如何。 Researchers at Imperial College London are conducting human trials for an inhalable gene therapy that could improve lung function for those with cystic fibrosis, regardless of their specific gene mutation. 治疗BI 3720931,使用扁豆矢量将功能性FCTR基因传送到气管细胞,有可能减少肺感染和呼吸问题。 The treatment, BI 3720931, uses a lentiviral vector to deliver a functional CFTR gene to airway cells, potentially reducing lung infections and breathing issues. LENTICLACIR 1号审判将评估安全性和有效性,预期到2027年初取得结果。 The LENTICLAIR 1 trial will assess safety and efficacy, with results expected by early 2027.